Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -107,254 | -87,872 | -62,707 | -30,470 | -135,117 |
| Depreciation Amortization | 1,440 | 844 | 434 | 75 | 16,001 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | -32 |
| Accounts receivable | N/A | 543 | 632 | -146 | 9,333 |
| Other Working Capital | -2,665 | -1,934 | 926 | -851 | -10,260 |
| Other Operating Activity | 4,403 | 4,007 | 3,747 | 2,632 | -4,291 |
| Operating Cash Flow | $-104,077 | $-84,413 | $-56,969 | $-28,760 | $-124,366 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 104,500 | 69,915 | 55,837 | 45,418 | 81,458 |
| PPE Investments | -429 | -488 | -488 | -36 | 5,898 |
| Investing Cash Flow | $104,071 | $69,427 | $55,349 | $45,383 | $87,356 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -16,415 | -16,415 | -16,415 | -16,415 | N/A |
| Common Stock Issued | 68,311 | 39,166 | 38,499 | 5,225 | 5,462 |
| Other Financing Activity | -421 | -421 | -414 | -174 | -467 |
| Financing Cash Flow | $51,476 | $22,330 | $21,670 | $-11,364 | $4,995 |
| Exchange Rate Effect | 32 | 32 | 32 | 32 | -4 |
| Beginning Cash Position | 14,311 | 14,311 | 14,311 | 14,311 | 46,329 |
| End Cash Position | 65,813 | 21,688 | 34,392 | 19,602 | 14,311 |
| Net Cash Flow | $51,502 | $7,377 | $20,082 | $5,291 | $-32,019 |
| Free Cash Flow | |||||
| Operating Cash Flow | -104,077 | -84,413 | -56,969 | -28,760 | -124,366 |
| Capital Expenditure | -488 | -488 | -488 | -36 | -321 |
| Free Cash Flow | -104,564 | -84,900 | -57,457 | -28,796 | -124,687 |